Previous studies have shown that FGF21 knockout or inhibitor of FGF21 can exacerbate the development of NAFLD/NASH (10, 62, 63), while pharmacological administration of FGF21 can effectively improve NAFLD/NASH (14, 64, 65). The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.